In the knockdown study, cells were treated with 10 nM of MAPK3 siRNA or MAPK14 siRNA (Invitrogen) and siRNA (Invitrogen) used as the negative control in Opti-MEM reduced serum culture medium for 24 h before MG treatment. The gene discussed is MAPK14; the disease is myasthenia gravis.